**Exhibit      10.22**

**PATENT        AND TECHNOLOGY LICENSE AGREEMENT**

**TABLE        OF CONTENTS**

| RECITALS                                                      | Page                  2  |
|---------------------------------------------------------------|--------------------------|
|                                                          |                     |
| I.                  EFFECTIVE DATE                            | Page                  2  |
|                                                          |                     |
| II.                  DEFINITIONS                              | Page                  2  |
|                                                          |                     |
| III.                  LICENSE                                 | Page                  4  |
|                                                          |                     |
| IV.                  CONSIDERATION, PAYMENTS AND REPORTS      | Page                  6  |
|                                                          |                     |
| V.                  SPONSORED RESEARCH                        | Page                  12 |
|                                                          |                     |
| VI.                  PATENTS AND INVENTIONS                   | Page                  12 |
|                                                          |                     |
| VII.                  INFRINGEMENT BY THIRD PARTIES           | Page                  13 |
|                                                          |                     |
| VIII.                  PATENT MARKING                         | Page                  14 |
|                                                          |                     |
| IX.                  INDEMNIFICATION AND INSURANCE            | Page                  14 |
|                                                          |                     |
| X.                  USE OF BOARD AND UTMDACC'S NAME           | Page                  16 |
|                                                          |                     |
| XI.                  CONFIDENTIAL INFORMATION AND PUBLICATION | Page                  16 |
|                                                          |                     |
| XII.                  ASSIGNMENT                              | Page                  18 |
|                                                          |                     |
| XIII.                  TERM AND TERMINATION                   | Page                  18 |

----

| XIV.                  WARRANTY: SUPERIOR-RIGHTS | Page                  21 |
|-------------------------------------------------|--------------------------|
|                                            |                     |
| XV.                  GENERAL                    | Page                  23 |
|                                            |                     |
| SIGNATURES                                      | Page                  26 |

**RECITALS**

| A. | BOARD                  owns certain PATENT RIGHTS and TECHNOLOGY RIGHTS related to LICENSED                  SUBJECT MATTER developed at                  UTMDACC. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| B. | BOARD,                  through UTMDACC, desires to have the LICENSED SUBJECT MATTER developed                  in                  the LICENSED FIELD and used for the benefit of LICENSEE, BOARD,                  SYSTEM,                  UTMDACC, the inventor(s), and the public as outlined in BOARD’s                  Intellectual Property Policy. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| C. | LICENSEE                  wishes to obtain a license from BOARD to practice LICENSED SUBJECT                  MATTER. |
|----|-----------------------------------------------------------------------------------------------------------------------|

**I.**
**EFFECTIVE        DATE**

| 1.1 | This                  AGREEMENT is effective as of the date written above ("EFFECTIVE                  DATE"). |
|-----|----------------------------------------------------------------------------------------------------------------|

**II.**
**DEFINITIONS**

| 2.1 | **AFFILIATE**                  means any business entity more than fifty percent (50%) owned by                  LICENSEE,                  any business entity which owns more than fifty percent (50%) of                  LICENSEE,                  or any business entity that is more than fifty percent (50%) owned                  by a                  business entity that owns more than fifty percent (50%) of                  LICENSEE. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 2.2 | **L****ICENSED                  FIELD**                  means the fields of human therapeutics and animal                  therapeutics. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------|

----

| 2.3 | **LICENSED                    PRODUCTS**                    means any product or service sold by LICENSEE comprising LICENSED                    SUBJECT                    MATTER pursuant to this AGREEMENT. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 2.4 | **LICENSED                    SUBJECT MATTER**                    means inventions and discoveries covered by PATENT RIGHTS or                    TECHNOLOGY                    RIGHTS within LICENSED FIELD. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 2.5 | **LICENSED                    TERRITORY**                    means worldwide. |
|-----|-------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 2.6 | **NET                    SALES**                    means the gross revenues received by LICENSEE from a SALE less                    sales                    discounts actually granted, sales and/or use taxes actually paid,                    import                    and/or export duties actually paid, outbound transportation actually                    prepaid or allowed, and amounts actually allowed or credited                    due to                    returns (not exceeding the original billing or invoice amount),                    all as                    recorded by LICENSEE in LICENSEE’s official books and records in                    accordance with generally accepted accounting practices and consistent                    with LICENSEE’s published financial statements and/or regulatory filings                    with the United States Securities and Exchange                    Commission. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 2.7 | **PATENT                    RIGHTS**                    means BOARD's rights in information or discoveries described                    in invention                    disclosures, or claimed in any patents, and/or patent applications,                    whether domestic or foreign, and all divisionals, continuations,                    continuations-in-part, reissues, reexaminations or extensions                    thereof, and                    any letters patent that issue thereon as defined in Exhibit I                    attached                    hereto. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 2.8 | **PHASE II CLINICAL STUDY**                  means: (a) that portion of the drug development and review process                  which                  provides for early controlled clinical studies conducted to obtain                  preliminary data on the effectiveness of an investigational new                  drug for a                  particular indication, as more specifically defined by the rules                  and                  regulations of the FDA, |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

** **

|   | including 21 C.F.R.§                  312.21 or any future revisions or substitutes therefor; or (b)                  a similar                  clinical study in any national jurisdiction other than the United                  States. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 2.9 | **PHASE                    IIb CLINICAL STUDY**                    means that portion of a PHASE II CLINICAL STUDY involving controlled                    dose                    ranging to evaluate the efficacy and safety of an investigational                    new drug                    in the target patient population and to define the optimal dosing                    regimen. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 2.10 | **S****ALE                    or SOLD**                    means the transfer or disposition of a LICENSED PRODUCT for value                    to a                    party other than LICENSEE or                    AFFILIATE. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 2.11 | **TECHNOLOGY                    RIGHTS**                    means BOARD's rights in any technical information, know-how,                    processes,                    procedures, compositions, devices, methods, formulae, protocols,                    techniques, software, designs, drawings or data created by the                    inventor(s)                    listed in Exhibit I at UTMDACC before the EFFECTIVE DATE, which                    are not                    claimed in PATENT RIGHTS but that are necessary for practicing                    PATENT                    RIGHTS. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**III.**
**LICENSE**

| 3.1 | BOARD, through UTMDACC, hereby grants to LICENSEE                  a                  royalty-bearing, exclusive license under LICENSED SUBJECT MATTER                  to                  manufacture, have manufactured, use, import, offer to sell and/or                  sell                  LICENSED PRODUCTS within LICENSED TERRITORY for use within LICENSED                  FIELD.** **This                  grant is subject to Sections 14.2 and 14.3 hereinbelow, the payment                  by                  LICENSEE to UTMDACC of all consideration as provided herein, the                  timely                  payment of all amounts due under any related sponsored research                  agreement                  between UTMDACC and LICENSEE in effect during this |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|

----

|   | AGREEMENT, and is further subject to the following                rights                retained by BOARD and UTMDACC to: |
|--------|---------------------------------------------------------------------------------------------------------------------------|

|   | (a) | Publish                  the general scientific findings from research related to LICENSED                  SUBJECT                  MATTER, subject to the terms of Article XI-Confidential Information                  and                  Publication; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | Use                  LICENSED SUBJECT MATTER for research, teaching, patient care, and                  other                  educationally-related, non-commercial                  purposes. |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 3.2 | LICENSEE                  may extend the license granted herein to any AFFILIATE provided                  that the                  AFFILIATE consents in writing to be bound by this AGREEMENT to                  the same                  extent as LICENSEE. LICENSEE agrees to deliver such contract to                  UTMDACC                  within thirty (30) calendar days following execution                  thereof. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 3.3 | LICENSEE                  may grant sublicenses under LICENSED SUBJECT MATTER consistent                  with the                  terms of this AGREEMENT provided that LICENSEE is responsible for                  its                  sublicensees relevant to this AGREEMENT, and for diligently collecting                  all                  amounts due LICENSEE from sublicensees. If a sublicensee pursuant                  hereto                  becomes bankrupt, insolvent or is placed in the hands of a receiver                  or                  trustee, LICENSEE, to the extent allowed under applicable law and                  in a                  timely manner, agrees to use its best reasonable efforts to collect                  all                  consideration owed to LICENSEE and to have the sublicense agreement                  confirmed or rejected by a court of proper jurisdiction. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 3.4 | LICENSEE                  must deliver to UTMDACC a true and correct copy of each sublicense                  granted                  by LICENSEE, and any modification or termination thereof, within                  thirty                  (30) calendar days after execution, modification, or                  termination. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3.5 | If                    this AGREEMENT is terminated pursuant to Article XIII-Term and                    Termination, BOARD and UTMDACC agree to accept as successors                    to LICENSEE,                    existing sublicensees in good standing at the date of termination                    provided                    that each such sublicensee consents in writing to be bound by                    all of the                    terms and conditions of this                    AGREEMENT. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 3.6 | UTMDACC                    grants LICENSEE an exclusive option to negotiate a worldwide,                    royalty-bearing exclusive license to any Improvements created                    by Dr.                    Waldemar Priebe at UTMDACC for two years from the EFFECTIVE DATE.                    For the                    purpose of this Section, “Improvements” means any analogs or derivative                    compounds based on the activity or structure of Tyrphostins.                    Such option                    shall be exercisable in the following manner: UTMDACC will promptly                    notify                    LICENSEE of any Improvements that are disclosed to its Office                    of                    Technology Commercialization. LICENSEE shall have three (3) months                    from                    such disclosure to notify UTMDACC of its desire to enter into                    such a                    license agreement, and a license agreement shall be negotiated                    in good                    faith within a period not to exceed six (6) months from LICENSEE's                    notification to UTMDACC of its desire to enter into a license                    agreement,                    or such period of time as to which the parties shall mutually                    agree.                    UTMDACC agrees that any license negotiated for Improvements will                    contain                    appropriate royalty stacking language which will prevent UTMDACC                    from                    receiving a royalty pursuant to both this AGREEMENT and any negotiated                    license for the Improvements. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**IV.**
**CONSIDERATION,        PAYMENTS AND REPORTS**

| 4.1 | In                  consideration of rights granted by BOARD to LICENSEE under this                  AGREEMENT,                  LICENSEE agrees to pay UTMDACC the                  following: |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | All                  out-of-pocket expenses incurred by UTMDACC in filing, prosecuting,                  enforcing and maintaining PATENT RIGHTS, and all such future expenses                  incurred by UTMDACC, for so long as, and in such countries as this                  AGREEMENT remains in effect. UTMDACC will invoice LICENSEE within                  thirty                  (30) calendar days of the EFFECTIVE DATE for expenses incurred                  as of that                  time and on a quarterly basis thereafter. The invoiced amounts                  will be due                  and payable by LICENSEE within thirty (30) calendar days of invoice;                  and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | A                  nonrefundable license documentation fee in the amount of $*. This                  fee will                  not reduce the amount of any other payment provided for in this                  ARTICLE                  IV, and is due and payable within thirty (30) calendar days after                  the                  AGREEMENT has been fully executed by all parties;                  and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | Nonrefundable                  annual license maintenance fees as                  follows: |
|--------|-----|---------------------------------------------------------------------------------------------|

|   | (i) | year                  one - $*, due within thirty (30) days of the first anniversary                  of the                  EFFECTIVE DATE; |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------|

|   | (ii) | year                  two - $*, due within thirty (30) days of the second anniversary                  of the                  EFFECTIVE DATE; |
|--------|------|------------------------------------------------------------------------------------------------------------------------------------------------|
|   | (iii) | year                  three - $*, due within thirty (30) days of the third anniversary                  of the                  EFFECTIVE DATE; |
|--------|-------|-------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |   |   |
|--------|--------|--------|

|   | (iv) | year                  four - $*, due within thirty (30) days of the fourth anniversary                  of the                  EFFECTIVE DATE; |
|--------|------|-------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (v) | year                  five - $*, due within thirty (30) days of the fifth anniversary                  of the                  EFFECTIVE DATE; and |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (vi) | year                  six and each subsequent year - $*, due within thirty (30) days                  of the                  seventh anniversary of the EFFECTIVE DATE and every anniversary                  of the                  EFFECTIVE DATE thereafter, provided that, upon the first SALE,                  the annual                  maintenance fee for that year and subsequent years will become                  a                  guaranteed minimum annual royalty of $* per year. |
|--------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | A                  running royalty as follows: |
|--------|-----|------------------------------------------------|

|   | (i) | *                  percent (*%) of NET SALES up to and including $* in NET SALES;                  and |
|--------|-----|--------------------------------------------------------------------------------------------------------|

| (e) | Milestone                  payments as follows due for each LICENSED PRODUCT used as a therapeutic: |
|-----|-----------------------------------------------------------------------------------------------------|

|   | (i) | $*                  due within thirty (30) days of an NDA filing for each LICENSED                  PRODUCT.                  As                  used herein, “NDA filing” shall mean the filing of a New Drug Application                  (as described in 21 C.F.R.§ 314.50 et. seq. or any future revisions or                  substitutes therefor) or a similar application seeking |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |   | Marketing Approval, as defined below, in the United                States or a country other than the United                States; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------|
|   | (ii) | $*                  due within thirty (30) days of Marketing Approval of each LICENSED                  PRODUCT. “Marketing                  Approval” means the approval or authorization required                  for the marketing, promotion and sale of LICENSED PRODUCT in a                  country,                  such as the issuance of an approval action on an NDA in the United                  States,                  or the issuance of its equivalent in a country other than the United                  States;                  and |
|--------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (iii) | $*                  due within thirty (30) days of the first SALE of each LICENSED                  PRODUCT;                  and |
|--------|-------|-----------------------------------------------------------------------------------------------------------------------------------|

| (f) | The                  following percentage of all consideration (other than (i) research                  and                  development money; (ii) payments received by LICENSEE from a sublicense                  as                  a result of the purchase or sale of debt or equity securities of                  LICENSEE                  by such sublicense; or (iii) monies received for the same milestone                  events                  outlined in Section 4.1(e)) received by LICENSEE from either (i)                  any                  sublicensee pursuant to Sections 3.3 and 3.4 hereinabove, or (ii)                  any                  assignee pursuant to Section 12.1 hereinbelow (in consideration                  for                  UTMDACC allowing the assignment), including but not limited to,                  royalties,                  up-front payments, marketing, distribution, franchise, option,                  license, or                  documentation fees, bonus, and certain milestone payments and equity                  securities not excluded above: |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (i) | prior                  to completion of a Phase IIb Clinical Study - * percent (*%);                  and |
|--------|-----|-----------------------------------------------------------------------------------------------------------|

|   | (ii) | on                  or after completion of Phase IIb Clinical Study -                  *                  percent (*%). |
|--------|------|-------------------------------------------------------------------------------------------------------------------------|

----

| 4.2 | Unless                  otherwise provided, all such payments are payable within thirty                  (30)                  calendar days after March 31, June 30, September 30, and December                  31 of                  each year during the term of this AGREEMENT, at which time LICENSEE                  will                  also deliver to UTMDACC a true and accurate report, giving such                  particulars of the business conducted by LICENSEE and its sublicensees,                  if                  any exist, during the preceding three calendar months under this                  AGREEMENT                  as necessary for UTMDACC to account for LICENSEE's payments hereunder.                  This report will include pertinent data, including, but not limited                  to: |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | the                  accounting methodologies used to account for and calculate the                  items                  included in the report and any differences in such accounting                  methodologies used by LICENSEE since the previous report;                  and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | a                  list of LICENSED PRODUCTS produced for the three (3) preceding                  calendar                  months categorized by the technology it relates to under PATENT                  RIGHTS;                  and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | the                  total quantities of LICENSED PRODUCTS produced by the category                  listed in                  Section 4.2(b); and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | the                  total SALES by the category listed in Section 4.2(b); and |
|--------|-----|--------------------------------------------------------------------------------|

|   | (e) | the                  calculation of NET SALES by the category listed in Section 4.2(b);                  and |
|--------|-----|--------------------------------------------------------------------------------------------------------------|

|   | (f) | the                  royalties so computed and due UTMDACC by the category listed in                  Section                  4.2(b) and/or minimum royalties;** **and |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (g) | all                  consideration received from each sublicensee or assignee and payments                  due                  UTMDACC; and |
|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------|
|   | (h) | all other amounts due UTMDACC                herein. |
|--------|-----|------------------------------------------------------|

----

| 4.3 | During                  the term of this AGREEMENT and for one (1) year thereafter, LICENSEE                  agrees to keep complete and accurate records of its and its sublicensees'                  SALES and NET SALES in sufficient detail to enable the royalties                  and other                  payments due hereunder to be determined. LICENSEE agrees to permit                  UTMDACC                  or its representatives, at UTMDACC's expense, to periodically examine                  LICENSEE’s books, ledgers, and records during regular business hours for                  the purpose of and to the extent necessary to verify any report                  required                  under this AGREEMENT. If any amounts due UTMDACC are determined                  to have                  been underpaid in an amount equal to or greater than five percent                  (5%) of                  the total amount due during the period so examined, then LICENSEE                  will pay                  the cost of the examination plus accrued interest at the highest                  allowable                  rate. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 4.4 | Within                  thirty (30) calendar days following each anniversary of the EFFECTIVE                  DATE, LICENSEE will deliver to UTMDACC a written progress report                  as to                  LICENSEE's (and any sublicensee’s) efforts and accomplishments during the                  preceding year in diligently commercializing LICENSED SUBJECT MATTER                  in                  the LICENSED TERRITORY and LICENSEE's (and sublicensees')                  commercialization plans for the upcoming                  year. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 4.5 | All                  amounts payable hereunder by LICENSEE will be paid in United States                  funds                  without deductions for taxes, assessments, fees, or charges of                  any kind.                  Checks are to be made payable to The University of Texas M. D.                  Anderson                  Cancer Center, and sent by |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 4.6 | No                  payments due or royalty rates owed under this AGREEMENT will be                  reduced as                  the result of co-ownership of LICENSED SUBJECT MATTER by BOARD                  and another                  party, including, but not limited to,                  LICENSEE. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**V.**
**SPONSORED        RESEARCH**

| 5.1 | If                  LICENSEE desires to sponsor research for or related to the LICENSED                  SUBJECT MATTER, and particularly where LICENSEE receives payments                  for                  sponsored research pursuant to a sublicense under this AGREEMENT,                  LICENSEE                  (a) will notify UTMDACC in writing of all opportunities to conduct                  this                  sponsored research (including clinical trials, if applicable),                  (b) solicit                  research and/or clinical proposals from UTMDACC for this purpose,                  and (c)                  will give good faith consideration to funding the proposals at                  UTMDACC. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**VI.**
**PATENTS        AND INVENTIONS**

| 6.1 | If                  after consultation with LICENSEE both parties agree that a new                  patent                  application should be filed for LICENSED SUBJECT MATTER, LICENSEE                  will pay                  the cost of |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | searching,                    preparing, filing, prosecuting and maintaining same. UTMDACC                    will keep                    LICENSEE fully informed on a timely basis of all activity on                    the filings                    related to the LICENSED SUBJECT MATTER and will provide LICENSEE                    with a                    copy of all applications and any documents received or filed                    during                    prosecution thereof for which LICENSEE has paid the cost of filing.                     For all applications and responses to office actions filed during                    the term                    of this AGREEMENT, LICENSEE will timely provide UTMDACC an initial                    draft                    and UTMDACC will review, finalize and file such documents. If                    LICENSEE                    notifies UTMDACC that it does not intend to pay the cost of an                    application, or if LICENSEE does not respond or make an effort                    to agree                    with UTMDACC on the disposition of rights of the subject invention,                    then                    UTMDACC may file such application at its own expense and LICENSEE’s rights                    to such invention under this AGREEMENT shall terminate in their                    entirety.                    The                    parties agree that they share a common legal interest to get                    valid                    enforceable patents and that LICENSEE will keep all privileged                    information                    received pursuant to this Section                    confidential. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**VII.**
**INFRINGEMENT        BY THIRD PARTIES**

| 7.1 | LICENSEE,                  at its expense, must enforce any patent exclusively licensed hereunder                  against infringement by third parties and is entitled to retain                  recovery                  from such enforcement. After reimbursement of LICENSEE’s reasonable legal                  costs and expenses related to such recovery, LICENSEE agrees to                  pay                  UTMDACC either: (a) the royalty detailed in Section 4.1(d) for                  any                  monetary recovery that is for sales of LICENSED PRODUCTS lost due                  to the                  infringement and fifty percent (50%) of punitive damages for willful                  infringement; or (b) fifty percent (50%) of reasonable royalties                  awarded                  and |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | punitive damages for willful infringement in any                recovery                in which the award is for reasonable royalties. LICENSEE must notify                UTMDACC in writing of any potential infringement within thirty (30)                calendar days of knowledge thereof. If LICENSEE decides not to pursue                an                infringement enforcement action within six month of knowledge of                such                infringement, LICENSEE will notify UTMDACC and then BOARD or UTMDACC                may,                at its discretion, after considering the commercially reasonable                bases for                LICENSEE’s decision not to pursue such infringement enforcement action,                pursue the enforcement of any patent licensed hereunder on behalf                of                itself and LICENSEE. In such case, the parties will discuss in good                faith                the appropriate settlement of such case and/or the appropriate                distribution of any recovery from such action, which shall depend                on                LICENSEE’s involvement and effect of the LICENSEE’s ability to                commercialize the LICENSED SUBJECT MATTER. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 7.2 | In                  any suit or dispute involving an infringer, the parties agree to                  cooperate                  fully with each other. At the request and expense of the party                  bringing                  suit, the other party will permit access during regular business                  hours, to                  all relevant personnel, records, papers, information, samples,                  specimens,                  and the like in its possession. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**VIII.**
**PATENT        MARKING**

| 8.1 | LICENSEE                  agrees that all packaging containing individual LICENSED PRODUCT(S),                  documentation therefor, and when possible for actual LICENSED PRODUCT(S)                  sold by LICENSEE, AFFILIATES, and/or sublicensees of LICENSEE will                  be                  permanently and legibly marked with the number of any applicable                  patent(s)                  licensed hereunder in accordance with each country's patent laws,                  including Title 35, United States                  Code. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**IX.**
**INDEMNIFICATION        AND INSURANCE**

| 9.1 | LICENSEE                    agrees to hold harmless and indemnify BOARD, SYSTEM, UTMDACC,                    its Regents,                    officers, employees, students and agents from and against any                    claims,                    demands, or causes of action whatsoever, costs of suit and reasonable                    attorney’s fees, including without limitation, those costs arising on                    account of any injury or death of persons or damage to property                    caused by,                    or arising out of, or resulting from, the exercise or practice                    of the                    rights granted hereunder by LICENSEE, its officers, its AFFILIATES                    or                    their officers, employees, agents or                    representatives.  |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 9.2 | In                  no event shall BOARD, SYSTEM or UTMDACC be liable for any indirect,                  special, consequential or punitive damages (including, without                  limitation,                  damages for loss of profits or expected savings or other economic                  losses,                  or for injury to persons or property) arising out of, or in connection                  with, this AGREEMENT or its subject matter, regardless of whether                  BOARD,                  SYSTEM or UTMDACC knows or should know of the possibility of such                  damages. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 9.3 | Beginning                  at the time when any LICENSED SUBJECT MATTER is being distributed                  or sold                  (including for the purpose of obtaining regulatory approvals) by                  LICENSEE                  or by a sublicensee, LICENSEE shall, at its sole cost and expense,                  procure                  and maintain commercial general liability insurance in amounts                  not less                  than $2,000,000 per incident and $2,000,000 annual aggregate, and                  LICENSEE                  shall use reasonable efforts to have the BOARD, SYSTEM, UTMDACC,                  its                  Regents, officers, employees, students and agents named as additional                  insureds. Such commercial general liability insurance shall provide:                  (i)                  product liability coverage; (ii) broad form contractual liability                  coverage                  for |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | LICENSEE's indemnification under this AGREEMENT;                and                (iii) coverage for litigation costs. The minimum amounts of insurance                coverage required herein shall not be construed to create a limit                of                LICENSEE's liability with respect to its indemnification under this                AGREEMENT. |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 9.4 | LICENSEE                  shall provide UTMDACC with written evidence of such insurance within                  thirty (30) days of its procurement. Additionally, LICENSEE shall                  provide                  UTMDACC with written notice of at least fifteen (15) days prior                  to the                  cancellation, non-renewal or material change in such insurance. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|

| 9.5 | LICENSEE                  shall maintain such commercial general liability insurance beyond                  the                  expiration or termination of this AGREEMENT during: (i) the period                  that                  any LICENSED SUBJECT MATTER developed pursuant to this AGREEMENT                  is being                  commercially distributed or sold by LICENSEE or by a sublicensee                  or agent                  of LICENSEE; and (ii) the five (5) year period immediately after                  such                  period. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**X.          USE OF BOARD AND UTMDACC'S NAME**

| 10.1 | LICENSEE                  will not use the name of (or the name of any employee of) UTMDACC,                  SYSTEM                  or BOARD in any advertising, promotional or sales literature, on                  its Web                  site, or for the purpose of raising capital without the advance                  express                  written consent of BOARD secured                  through: |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**XI.**
**CONFIDENTIAL        INFORMATION AND PUBLICATION**

| 11.1 | UTMDACC                  and LICENSEE each agree that all information contained in documents                  marked                  "confidential" and forwarded to one by the other (i) are to be                  received in                  strict confidence, (ii) are to be used only for the purposes of                  this                  AGREEMENT, and (iii) will not be disclosed by the recipient party                  (except                  as required by law or court order), its agents or employees without                  the                  prior written consent of the other party, except to the extent                  that the                  recipient party can establish by competent written proof that such                  information: |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | was                  in the public domain at the time of disclosure;                  or |
|--------|-----|------------------------------------------------------------------------------------------|

|   | (b) | later                  became part of the public domain through no act or omission of                  the                  recipient party, its employees, agents, successors or assigns;                  or |
|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | was                  lawfully disclosed to the recipient party by a third party having                  the                  right to disclose it; or |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | was                  already known by the recipient party at the time of disclosure;                  or |
|--------|-----|----------------------------------------------------------------------------------------------------------|

|   | (e) | was                  independently developed by the recipient party without use of the                  other                  party’s confidential information; or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (f) | is                  required by law or regulation to be disclosed. |
|--------|-----|--------------------------------------------------------------------|

| 11.2 | Each                  party’s obligation of confidence hereunder will be fulfilled by using                  at                  least the same degree of care with the other party's confidential                  information as it uses to protect its |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | own confidential information, but always at least                a                reasonable degree of care. This obligation will exist while this                AGREEMENT                is in force and for a period of three (3) years                thereafter. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 11.3 | UTMDACC                  reserves the right to publish the general scientific findings from                  research related to LICENSED SUBJECT MATTER, with due regard to                  the                  protection of LICENSEE’s confidential information. UTMDACC will submit the                  manuscript of any proposed publication to LICENSEE at least thirty                  (30)                  calendar days before publication, and LICENSEE shall have the right                  to                  review and comment upon the publication in order to protect LICENSEE’s                  confidential information. Upon LICENSEE’s request, publication may be                  delayed up to sixty (60) additional calendar days to enable LICENSEE                  to                  secure adequate intellectual property protection of LICENSEE’s                  confidential information that would otherwise be affected by the                  publication. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**XII.**
**ASSIGNMENT**

| 12.1 | Except                  in connection with the sale of all of LICENSEE's assets to a third                  party,                  this AGREEMENT may not be assigned by LICENSEE without the prior                  written                  consent of UTMDACC, which will not be unreasonably                  withheld. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**XIII.**
**TERM        AND TERMINATION**

| 13.1 | Subject                  to Sections 13.3, 13.4 hereinbelow, the term of this AGREEMENT                  is from the                  EFFECTIVE DATE to the full end of the term or terms for which PATENT                  RIGHTS have not expired. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|

| 13.2 | Any                  time after two (2) years from the EFFECTIVE DATE, BOARD or UTMDACC                  have                  the right to terminate this license in any national political jurisdiction                  within the |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | LICENSED TERRITORY if LICENSEE, within ninety                (90)                calendar days after receiving written notice from UTMDACC of the                intended                termination, fails to provide written evidence satisfactory to UTMDACC                that LICENSEE or its sublicensee(s) has commercialized or is actively                and                effectively attempting to commercialize a licensed invention in such                jurisdiction(s). The following definitions apply to Section 13.2:                (a)                "commercialize" means having SALES in such jurisdiction; (b) "active                attempts to commercialize" means having an effective, ongoing and                active                research, development, manufacturing, marketing or sales program                as                appropriate, directed toward obtaining regulatory approval, and/or                production and/or SALES in any jurisdiction, and has provided plans                acceptable to UTMDACC, in its sole discretion, to commercialize licensed                inventions in the jurisdiction(s) that UTMDACC intends to                terminate. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 13.3 | Subject                  to any rights herein which survive termination, this AGREEMENT                  will                  earlier terminate in its entirety: |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (a) | automatically,                  if LICENSEE becomes bankrupt or insolvent and/or if the business                  of                  LICENSEE shall be placed in the hands of a receiver, assignee,                  or trustee,                  whether by voluntary act of LICENSEE or otherwise;                  or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | upon                  thirty (30) calendar days written notice from UTMDACC, if LICENSEE                  breaches or defaults on the payment or report obligations of ARTICLE                  IV,                  or use of name obligations of ARTICLE X, unless, before the end                  of the                  such thirty (30)-calendar day notice period, LICENSEE has cured                  the                  default or breach to UTMDACC’s satisfaction, and so notifies UTMDACC,                  stating the manner of the cure; or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (c) | upon                  ninety (90) calendar days written notice from UTMDACC if LICENSEE                  breaches                  or defaults on any other obligation under this AGREEMENT, unless,                  before                  the end of the such ninety (90) calendar-day notice period, LICENSEE                  has                  cured the default or breach to UTMDACC’s satisfaction and so notifies                  UTMDACC, stating the manner of the cure; or |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (d) | at                  any time by mutual written agreement between LICENSEE and UTMDACC                  upon one                  hundred eighty (180) calendar days written notice to all parties                  and                  subject to any terms herein which survive termination;                  or |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | if                  Section 13.2 is invoked; or |
|--------|-----|-------------------------------------------------|

|   | (f) | if                  LICENSEE has defaulted or been late on its payment obligations                  pursuant to                  the terms of this AGREEMENT on any two (2) occasions in a twelve                  (12)                  month period. |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.4 |   | Upon termination of this                AGREEMENT: |
|------|--------|----------------------------------------------------|
|   | (a) | nothing                  herein will be construed to release either party of any obligation                  maturing prior to the effective date of the termination;                  and |
|--------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (b) | LICENSEE                  covenants and agrees to be bound by the provisions of Articles                  IX                  (Indemnification and Insurance), X (Use of Board and UTMDACC’s Name) and                  XI (Confidential Information and Publication) of this AGREEMENT;                  and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (c) | LICENSEE                  may, after the effective date of the termination, sell all LICENSED                  PRODUCTS and parts therefor that it has on hand at the date of                  termination, if LICENSEE pays the earned royalty thereon and any                  other                  amounts due pursuant to Article IV of this AGREEMENT; and |
|--------|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | (d) | Subject                  to Section 13.4(c),** **LICENSEE                  agrees to cease and desist any use and all SALE of the LICENSED                  SUBJECT                  MATTER and LICENSED PRODUCTS upon termination of this AGREEMENT;                  and |
|--------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (e) | LICENSEE                  grants to BOARD and UTMDACC a nonexclusive royalty bearing license                  with                  the right to sublicense others with respect to improvements made                  by                  LICENSEE (including improvements licensed by LICENSEE from third                  parties)                  in the LICENSED SUBJECT MATTER. LICENSEE and UTMDACC agree to negotiate                  in                  good faith the royalty rate for the nonexclusive license. BOARD's                  and                  UTMDACC’s right to sublicense others hereunder is solely for the purpose                  of permitting others to develop and commercialize the entire technology                  package. |
|--------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**XIV.**
**WARRANTY:        SUPERIOR-RIGHTS**

| 14.1 | Except                  for the rights, if any, of the Government of the United States                  of America                  as set forth below and except as set forth in Section 14.5, BOARD                  represents and warrants its belief that (a) it is the owner of                  the entire                  right, title, and interest in and to LICENSED SUBJECT MATTER, (b)                  it has                  the sole right to grant licenses thereunder, and (c) it has not                  knowingly                  granted licenses thereunder to any other entity that would restrict                  rights                  granted hereunder except as stated                  herein. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 14.2 | LICENSEE                  understands that the LICENSED SUBJECT MATTER may have been developed                  under                  a funding agreement with the Government of the United States of                  America                  and, if so, that the Government may have certain rights relative                  thereto.                  This AGREEMENT is explicitly made subject to the Government's rights                  under                  any such agreement and any applicable law or regulation, including                  P.L.                  96-517 as amended by |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | P.L. 98-620. To the extent that there is a conflict                  between any such agreement, applicable law or regulation and this                  AGREEMENT, the terms of such Government agreement, applicable law                  or                  regulation shall prevail. LICENSEE agrees that LICENSED PRODUCTS                  used or                  SOLD in the United States will be manufactured substantially in                  the United                  States, unless a written waiver is obtained in advance from the                  GOVERNMENT. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 14.3 | LICENSEE                    understands and agrees that BOARD and UTMDACC, by this AGREEMENT,                    make no                    representation as to the operability or fitness for any use,                    safety,                    efficacy, approvability by regulatory authorities, time and cost                    of                    development, patentability, and/or breadth of the LICENSED SUBJECT                    MATTER.                    BOARD and UTMDACC, by this AGREEMENT, also make no representation                    as to                    whether any patent covered by PATENT RIGHTS is valid or as to                    whether                    there are any patents now held, or which will be held, by others                    or by                    BOARD or UTMDACC in the LICENSED FIELD, nor does BOARD and UTMDACC                    make                    any representation that the inventions contained in PATENT RIGHTS                    do not                    infringe any other patents now held or that will be held by others                    or by                    BOARD. |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 14.4 | LICENSEE, by execution hereof, acknowledges,                  covenants                  and agrees that LICENSEE has not been induced in any way by BOARD,                  SYSTEM,                  UTMDACC or employees thereof to enter into this AGREEMENT, and                  further                  warrants and represents that (a) LICENSEE has conducted sufficient                  due diligence with respect to all items and issues pertaining to                  this                  AGREEMENT; and (b) LICENSEE has adequate knowledge and |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | expertise, or has used knowledgeable and expert                consultants, to adequately conduct such due diligence, and agrees                to                accept all risks inherent herein. |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 14.5 | LICENSEE                  understands and acknowledges that Dr. Bogdan Lesyng, of Warsaw,                  Poland,                  has asserted that he is a co-inventor on the patent applications                  under                  PATENT RIGHTS. If appropriate, UTMDACC will add Dr. Lesyng as an                  inventor                  to such applications. UTMDACC will consult with LICENSEE prior                  to any                  decision to add Dr. Lesyng as an inventor. If the decision is made                  to add                  Dr. Lesyng as an inventor, LICENSEE shall have a sixty (60) day                  option                  period to notify UTMDACC that it desires to take a non-exclusive                  lincese,                  in which case the parties will work together in good faith to promptly                  terminate this agreement and contemporaneously enter into a non-exclusive                  license to the LICENSED SUBJECT MATTER based on UTMDACC’s standard form                  and all appropriate consideration (e.g., annual license maintenance                  fees,                  running royalties, and milestone payments) due after the effective                  date of                  the non-exclusive license will be reduced from this AGREEMENT by                  thirty                  percent (30%). |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**XV.**
**GENERAL**

| 15.1 | This                  AGREEMENT constitutes the entire and only agreement between the                  parties                  for LICENSED SUBJECT MATTER, and all other prior negotiations,                  representations, agreements and understandings are superseded hereby.                  No                  agreements altering or supplementing the terms hereof will be made                  except                  by a written document signed by both                  parties. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   |   |
|--------|--------|
| 15.2 | Any                  notice required by this AGREEMENT must be given by prepaid, first                  class,                  certified mail, return receipt requested, and addressed in the                  case of                  UTMDACC to: |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 15.3 | LICENSEE                  must comply with all applicable federal, state and local laws and                  regulations in connection with its activities pursuant to this                  AGREEMENT. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 15.4  | This                  AGREEMENT will be construed and enforced in accordance with the                  laws of                  the United States of America and of the State of Texas, without                  regard to                  its conflict of law provisions. The Texas State Courts of Harris                  County,                  Texas (or, if there is exclusive federal jurisdiction, the United                  States                  District Court for the Southern District of Texas) shall have exclusive                  jurisdiction and venue over any dispute arising out of this AGREEMENT,                  and                  LICENSEE consents to the jurisdiction of such courts; however,                  nothing                  herein shall be deemed as a waiver by BOARD, SYSTEM or UTMDACC                  of its                  sovereign immunity. |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|

----

| 15.5 | Any                  dispute or controversy arising out of or relating to this AGREEMENT,                  its                  construction or its actual or alleged breach will be decided by                  mediation.                  If the mediation does not result in a resolution of such dispute                  or                  controversy, it will be finally decided by an appropriate method                  of                  alternate dispute resolution, including without limitation, arbitration,                  conducted in the city of Houston, Harris County, Texas, in accordance                  with                  the applicable, then-current procedures of the American Arbitration                  Association. The arbitration panel will include members knowledgeable                  in                  the evaluation of the LICENSED SUBJECT MATTER. Judgment upon the                  award                  rendered may be entered in the highest court or forum having jurisdiction,                  state or federal. The provisions of this Section 15.5 will not                  apply to                  decisions on the validity of patent claims or to any dispute or                  controversy as to which any treaty or law prohibits such arbitration.                  The                  decision of the arbitration must be sanctioned by a court of law                  having                  jurisdiction to be binding upon and enforceable by the                  parties. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 15.6 | Failure of BOARD or UTMDACC to enforce a right                under this                AGREEMENT will not act as a waiver of right or the ability to later                assert                that right relative to the particular situation                involved. |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 15.7 | Headings included herein are for convenience only                and                will not be used to construe this AGREEMENT. |
|------|----------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 15.8 | If any part of this AGREEMENT is for any reason                found to                be unenforceable, all other parts nevertheless will remain                enforceable. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**IN        WITNESS WHEREOF**

| BOARD                  OF REGENTS OF THEUNIVERSITY                  OF TEXAS SYSTEM                                                                                |   |   | CALLISTO                  PHARMACEUTICALS, INC.                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|-------------------------------------------------------------------------------------------------------|
|                                                                                                                                                               |   |   |                                                                                                  |
| /s/ John                Mendelsohn                                                                                                                            |   |   | /s/ Gary                S.                Jacob                                                  |
|                                                                                                                                                                    |   |   |                                                                                                       |
| John                  Mendelsohn, M.D.PresidentThe                  University of TexasM.                  D. Anderson Cancer CenterDate:                  1/10/06 |   |   | Gary                  S. Jacob, Ph.D.Chief                  Executive Officer  Date:12/7/05 |

| THE                  UNIVERSITY OF TEXAS M.                  D. ANDERSON CANCER CENTER                                                                                                  |   |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|
|                                                                                                                                                                                    |   |   |
| /s/ Leon                Leach                                                                                                                                                      |   |   |
|                                                                                                                                                                                         |   |   |
| Leon                  Leach Executive                  Vice PresidentThe                  University of TexasM.                  D. Anderson Cancer CenterDate:                  1/6/06 |   |   |

| Approved as to Content:                                                                                                                                                        |   |   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|
|                                                                                                                                                                           |   |   |
| /s/ Christopher                C. Capelli                                                                                                                                 |   |   |
|                                                                                                                                                                                |   |   |
| Christopher                  C. Capelli, M.D. Vice                  President, Technology TransferM.                  D. Anderson Cancer CenterDate:                  12/15/05 |   |   |

----

**EXHIBIT        I**

----